دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Clinical Images: Liver nodular regenerative hyperplasia in antisynthetase syndrome
Yi-Ning Yen, Hsien-Tzung Liao
doi : 10.1002/acr2.11491
Side Effects of Methotrexate and Tumor Necrosis Factor Inhibitors: Differences in Tolerability Among Patients With Psoriatic Arthritis and Rheumatoid Arthritis
Alexis Ogdie, Ervant J. Maksabedian Hernandez, Yomei Shaw, Bradley Stolshek, Kaleb Michaud
doi : 10.1002/acr2.11467
Construction of an Administrative Osteoarthritis Severity Index
Sarah C. Gebauer, Timothy Chrusciel, Joanne Salas, Jamil Neme, Leigh F. Callahan, Jeffrey Scherrer
doi : 10.1002/acr2.11490
Electronic health record (EHR) databases are a powerful resource to investigate clinical trajectories of osteoarthritis (OA). There are no existing EHR tools to evaluate risk for knee arthroplasty (KA). We developed an OA severity index (OASI) using EHR data and demonstrate the index's association with time to KA.
Characteristics and Outcomes of People With Gout Hospitalized Due to COVID-19: Data From the COVID-19 Global Rheumatology Alliance Physician-Reported Registry
Kanon Jatuworapruk, Anna Montgomery, Milena Gianfrancesco, Richard Conway, Laura Durcan, Elizabeth R. Graef, Aruni Jayatilleke, Helen Keen, Adam Kilian, Kristen Young, Loreto Carmona, Adriana Karina Cogo, AlàDuarte-GarcÃÂa, Laure Gossec, Rebecca Hasseli, Kimme L. Hyrich, Vincent Langlois, Saskia Lawson-Tovey, Armando Malcata, Elsa F Mateus, Martin Schafer, Carlo Alberto Scirè, Valgerdur Sigurdardottir, Jeffrey A. Sparks, Anja Strangfeld, Ricardo M. Xavier, Suleman Bhana, Monique Gore-Massy, Jonathan Hausmann, Jean W. Liew, Emily Sirotich, Paul Sufka, Zach Wallace, Pedro M. Machado, Jinoos Yazdany, Rebecca Grainger, Philip C. Robinson
doi : 10.1002/acr2.11495
To describe people with gout who were diagnosed with coronavirus disease 2019 (COVID-19) and hospitalized and to characterize their outcomes.
Association of Race and Ethnicity With Medication Use for Pediatric Lupus in the Childhood Arthritis and Rheumatology Research Alliance Registry
Jordan E. Roberts, Laura Berbert, Joyce Chang, Mary Beth F. Son, for the Childhood Arthritis and Rheumatology Research Alliance Registry Investigators
doi : 10.1002/acr2.11494
Black and Hispanic children with pediatric lupus (pSLE) have higher morbidity and mortality than non-Hispanic White children. The extent to which differences in outcomes are due to treatment disparities, including medication use, is unknown. We aimed to determine whether medication use in pSLE is associated with race and ethnicity in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry.
Development and Testing of an Electronic Health Record-Integrated Patient-Reported Outcome Application and Intervention to Improve Efficiency of Rheumatoid Arthritis Care
Daniel H. Solomon, Anuj K. Dalal, Adam B. Landman, Leah Santacroce, Hallie Altwies, Jackie Stratton, Robert S. Rudin
doi : 10.1002/acr2.11498
Many patients with rheumatoid arthritis (RA) have difficulty finding clinicians to treat them because of workforce shortages. We developed an app to address this problem by improving care efficiency. The app collects patient-reported outcomes (PROs) and can be used to inform visit timing, potentially reducing the volume of low-value visits. We describe the development process, intervention design, and planned study for testing the app.
Preferences and Insights for Participation in a Rheumatoid Arthritis Clinical Prevention Trial: A Mixed-Methods Study
Chelsie L. Fleischer, Elizabeth A. Bemis, Marie L. Feser, Vasilisa A. Kormendi, Alvina Zhang, Katherine Ketcham, Sharon D. White, Christopher C. Striebich, Kevin D. Deane, Mark Harrison
doi : 10.1002/acr2.11500
In rheumatoid arthritis (RA), anti–citrullinated protein antibodies (ACPA) can be elevated prior to inflammatory arthritis (IA). The potential to intervene in people with ACPA positivity underpins the development of prevention trials in RA. The Research Participation Influences Study examined factors influencing the decisions of individuals who are ACPA(+) to participate in a prevention trial using qualitative and quantitative methods.
Randomized Trial of Tocilizumab in the Treatment of Refractory Adult Polymyositis and Dermatomyositis
Chester V. Oddis, Howard E. Rockette, Lei Zhu, Diane C. Koontz, David Lacomis, Swamy Venturupalli, Siamak Moghadam-Kia, Dana P. Ascherman, Leslie Crofford, Mazen M. Dimachkie
doi : 10.1002/acr2.11493
To assess the efficacy and tolerability of tocilizumab in a multicenter, randomized, double-blind, placebo-controlled trial in refractory adult patients with dermatomyositis (DM) and polymyositis (PM).
Clinical Images: Late-stage hydroxychloroquine-associated retinopathy
Mary K. Munsell, Daniel A. Balikov, David N. Zacks
doi : 10.1002/acr2.11502
